Antibody directed against human YKL-40 increases tumor volume in a human melanoma xenograft model in scid mice
Standard
Antibody directed against human YKL-40 increases tumor volume in a human melanoma xenograft model in scid mice. / Salamon, Johannes; Hoffmann, Tatjana; Elies, Eva; Peldschus, Kersten; Johansen, Julia S; Lüers, Georg; Schumacher, Udo; Wicklein, Daniel.
In: PLOS ONE, Vol. 9, No. 4, 01.01.2014, p. e95822.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Antibody directed against human YKL-40 increases tumor volume in a human melanoma xenograft model in scid mice
AU - Salamon, Johannes
AU - Hoffmann, Tatjana
AU - Elies, Eva
AU - Peldschus, Kersten
AU - Johansen, Julia S
AU - Lüers, Georg
AU - Schumacher, Udo
AU - Wicklein, Daniel
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Induced overexpression of the secretory protein YKL-40 promotes tumor growth in xenograft experiments. We investigated if targeting YKL-40 with a monoclonal antibody could inhibit tumor growth. YKL-40 expressing human melanoma cells (LOX) were injected subcutenously in Balb/c scid mice. Animals were treated with intraperitoneal injections of anti-YKL-40, isoptype control or PBS. Non-YKL-40 expressing human pancreatic carcinoma cell line PaCa 5061 served as additional control. MR imaging was used for evaluation of tumor growth. Two days after the first injections of anti-YKL-40, tumor volume had increased significantly compared with controls, whereas no effects were observed for control tumors from PaCa 5061 cells lacking YKL-40 expression. After 18 days, mean tumor size of the mice receiving repeated anti-YKL-40 injections was 1.82 g, >4 times higher than mean tumor size of the controls (0.42 g). The effect of anti-YKL-40 on the increase of tumor volume started within hours after injection and was dose dependent. Intratumoral hemorrhage was observed in the treated animals. The strong effect on tumor size indicates important roles for YKL-40 in melanoma growth and argues for a careful evaluation of antibody therapy directed against YKL-40.
AB - Induced overexpression of the secretory protein YKL-40 promotes tumor growth in xenograft experiments. We investigated if targeting YKL-40 with a monoclonal antibody could inhibit tumor growth. YKL-40 expressing human melanoma cells (LOX) were injected subcutenously in Balb/c scid mice. Animals were treated with intraperitoneal injections of anti-YKL-40, isoptype control or PBS. Non-YKL-40 expressing human pancreatic carcinoma cell line PaCa 5061 served as additional control. MR imaging was used for evaluation of tumor growth. Two days after the first injections of anti-YKL-40, tumor volume had increased significantly compared with controls, whereas no effects were observed for control tumors from PaCa 5061 cells lacking YKL-40 expression. After 18 days, mean tumor size of the mice receiving repeated anti-YKL-40 injections was 1.82 g, >4 times higher than mean tumor size of the controls (0.42 g). The effect of anti-YKL-40 on the increase of tumor volume started within hours after injection and was dose dependent. Intratumoral hemorrhage was observed in the treated animals. The strong effect on tumor size indicates important roles for YKL-40 in melanoma growth and argues for a careful evaluation of antibody therapy directed against YKL-40.
U2 - 10.1371/journal.pone.0095822
DO - 10.1371/journal.pone.0095822
M3 - SCORING: Journal article
C2 - 24752554
VL - 9
SP - e95822
JO - PLOS ONE
JF - PLOS ONE
SN - 1932-6203
IS - 4
ER -
